T Cell Receptor Technology (TCRs) | Juno Therapeutics

T Cell Receptor Technology

TCR Therapy Starts from Inside the Cell

Unlike CAR T cells that recognize proteins expressed on the surface, T cell Receptors (TCRs) can recognize tumor-specific proteins on the inside of cells. When tumor-specific proteins are broken into fragments, they show up on the cell surface with another protein called major histocompatibility complex, or MHC. TCRs are engineered to recognize a tumor-specific protein fragment/MHC combination.1

Major histocompatibility complex (MHC) class I molecules present peptide antigens for recognition by CD8+ T cell receptors.2
The MHC class I molecule presents peptide antigens that are derived from intracellular proteins.2
The T cell receptor (TCR) is a heterodimer consisting of two subunits, TCRα and TCRβ. Each subunit contains a constant region that anchors the receptor to the cell membrane and a hypervariable region that functions in antigen recognition.2
  1. Morris EC, Stauss HJ. Optimizing T-cell receptor gene therapy for hematologic malignancies. Blood. 2016:127:3305-3311.
  2. Murphy K, Weaver C. Immunobiology. Chapter 4. Antigen recognition by T cells. 9th Edition, 2017; New York: Garland Science.

Moving the Science Forward

TCRs are still in early development but an exciting area of the Juno pipeline. Learn more about the latest advances in the field.